JREE:F:F-JPMorgan ETFs (Ireland) ICAV - Europe Research Enhanced Index Equity UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 42.8

Change

+0.17 (+0.39)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.24 (+0.88%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

USD 109.59B
SXR8:F iShares Core S&P 500 UCITS ETF..

-0.28 (-0.05%)

USD 96.22B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.44 (+0.79%)

USD 91.00B
SXRZ:F iShares VII PLC - iShares Nikk..

+1.85 (+0.78%)

USD 54.70B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.12 (+0.81%)

USD 52.21B
VUAA:F Vanguard S&P 500 UCITS Acc

N/A

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.45 (+0.46%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.01 (-0.10%)

USD 40.38B
0ZC:F Zscaler Inc

+1.24 (+0.81%)

USD 37.92B

ETFs Containing JREE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.35% 62% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.35% 59% D- 57% F
Trailing 12 Months  
Capital Gain 13.86% 59% D- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.86% 55% F 55% F
Trailing 5 Years  
Capital Gain 55.55% 76% C+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.55% 76% C+ 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 11.14% 78% C+ 72% C
Dividend Return 11.14% 75% C 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.74% 54% F 82% B
Risk Adjusted Return 87.43% 93% A 92% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike